2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1139

Management of Gout – a Survey for Healthcare Providers in South Australia
Abstract Number: 1140

Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study
Abstract Number: 1141

Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Abstract Number: 1142

A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality
Abstract Number: 1143

The Patient Education for Gout Patients Ameliorate the Patients’ Satisfaction and Serum Uric Acid Level
Abstract Number: 1144

Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Abstract Number: 1145

Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals
Abstract Number: 1146

Associations between Gout and Cancer in an Nhanes Cohort
Abstract Number: 1147

Macrophage Activation Syndrome or Acquired Hemophagocytic Lymphohistiocytosis in Adults: Demographics, Clinical Characteristics, and Survivorship in an American Academic Medical Center
Abstract Number: 1148

Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response
Abstract Number: 1149

Clinical Implications of Ultrasonography (US) in Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparative Investigation By US between Auricle of RP, Repeated Trauma and Healthy Subject
Abstract Number: 1150

Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.
Abstract Number: 1151

Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration
Abstract Number: 1152

Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease
Abstract Number: 1153

Rheumatic Manifestations of Whim Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].